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n 2004, almost 5 million people 
became newly infected with HIV, 
emphasizing the continuous need 
for effective prevention strategies. The 
development of an effective preventive 
vaccine faces many difﬁ  culties and 
is not likely to occur within the next 
decade. Behavioural changes, such 
as consistent and correct condom 
use and abstinence from high-risk 
behaviour, probably contributed to the 
fall in HIV incidence recently reported 
in several African countries and in 
India [1]. Recently, it was shown that 
male circumcision reduced the risk 
of acquiring HIV by 60% [2] and the 
risk of male-to-female transmission 
by 30% [3]. However, behavioural 
interventions may not be able to curb 
the HIV epidemic as much as needed, 
prompting the need to ﬁ  nd additional, 
more effective preventive strategies. 
There is also a need for “female-
initiated intervention”. Women around 
the globe continue to be infected with 
HIV by their male partners and often 
feel unable to insist on condom use. 
    Alternatives to behavioural strategies 
include those that are based on 
drugs. Anti-HIV vaginal microbicides, 
which may offer women a means of 
protecting themselves from infection, 
are currently being evaluated [4]. Also, 
rectally applied microbicides have 
proven to effectively prevent infection 
in macaques challenged via this 
transmission route [5]. However, like 
male circumcision, this strategy may 
not provide protection against other 
routes of HIV transmission, such as oral 
or intravenous transmission.
    Oral antiretroviral pre-exposure 
prophylaxis (PREP) in high-risk 
populations may be a more reliable 
tool in preventing transmission of HIV 
[6]. Limited animal model data suggest 
that antiretroviral drugs may prevent 
infection when taken prior to, at the 
time of, and/or after HIV exposure 
[7–10]. Theoretically, preventing HIV 
infection could be done by blocking 
any step in the HIV life cycle. Blocking 
a step prior to integration of proviral 
DNA into the host DNA is believed to 
have greater potential since this way the 
permanent integration of proviral HIV 
is averted. 
    The Initial PREP Trials
    For the initial trials studying the 
safety and efﬁ  cacy of PREP, tenofovir 
disoproxil fumarate (TDF) was 
selected, based on its encouraging data 
from animal studies. So far, no other 
antiretroviral drug has been evaluated 
in human PREP studies. However, 
there is no reason why PREP research 
should be restricted to TDF. 
    In the absence of animal data, other 
drugs with antiviral effects similar to 
TDF represent possible alternatives. 
Also, recent data seem to show rapid 
in vitro selection of K65R mutation 
in HIV subtype C (the most prevalent 
subtype worldwide) compared to 
other subtypes, suggesting the need 
for caution when using the drug on 
a wide scale [11]. Recent results also 
suggest that the protective effect of 
TDF monotherapy may be overcome 
by repeated exposures to the virus in 
animal models [12], providing further 
impetus not to focus on TDF alone in 
PREP research. 
    In this paper, we formulate criteria 
for an optimal PREP drug candidate 
based on a literature review and our 
expert opinion where appropriate. 
Also, we evaluate existing antiviral drug 
classes for their suitability in PREP. 
    Criteria for PREP Drug Candidates
    The biological basis for PREP is 
that the drug/regimen is capable of 
averting new HIV infections. In the 
absence of data from randomised 
controlled clinical trials, this 
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requirement, as well as some others, 
can be translated into speciﬁ  c criteria 
that should be met by a PREP drug.
      Safety proﬁ  le.   Safety is an important 
issue for all drugs used in clinical 
practice, especially in individuals 
without disease. Since a PREP drug 
may be taken regularly over a very long 
time period (years), the best candidate 
drugs should have a favorable safety 
proﬁ  le based on extensive clinical 
experience and large safety databases.
      Ease of use.   PREP is only likely to 
be successful as a strategy if it can be 
easily adopted into daily life. No formal 
criteria for “ease of use” have been 
deﬁ  ned for the PREP setting, but ease 
of use would require convenient drug 
dosing options, such as once daily or 
once weekly dosing, a limited number 
of pills, the absence of strict food 
regulations when taking the drug, and 
excellent tolerability. Ideally, PREP 
should offer continued protection even 
if an occasional dose is missed. Thus, the 
pharmacokinetic and toxicity proﬁ  les 
of the compound will be critical to the 
success of the PREP strategy. 
      Mode of action and pharmacology.   
Theoretically, prevention of integration 
of the proviral DNA into the host cell 
genome during the very ﬁ  rst replicative 
cycle is the preferred mode of action. If 
the viral genome has become integrated 
in the host cell, there is a danger that 
infectious progeny could be expressed 
at a later stage and the individual 
would become infected. However, 
recent data suggest that a minimal 
seeding population of infected cells is 
required in the mucosa for infection to 
become established [13]. Therefore, 
reducing this seeding population or 
its dissemination of progeny virus may 
be enough to block establishment of 
infection. From a pharmacological 
perspective, the active metabolite of 
the candidate drug should achieve 
sufﬁ  ciently high drug levels at the sites 
of virus entry into the body and at sites 
of viral replication and should be active 
in all cell types that are relevant to HIV 
transmission. However, adequate levels 
for the prevention of HIV transmission 
are not known at present.
      Antiviral proﬁ  le.   First, the PREP 
compound should retain its preventive 
effect against drug-resistant viral strains 
selected by other antiviral drugs used in 
the same geographic area. Second, in 
case the PREP regimen fails to prevent 
infection with HIV, and drug-resistant 
viral strains are selected in this process, 
the impact of this drug resistance 
on subsequent treatment response 
should be minimised. The criteria that 
should apply to a potential PREP drug 
regarding its antiviral proﬁ  le are shown 
in Box 1. 
      Cost-effectiveness.   In order for PREP 
treatment to be widely introduced, 
the cost-effectiveness ratio needs to 
compare favorably with other common 
medical interventions or procedures 
in developing countries. The cost-
effectiveness of PREP depends on 
three key factors: (1) the price of the 
PREP treatment used (US$ per person-
year of treatment); (2) the efﬁ  cacy of 
the PREP (percentage reduction in 
incidence of HIV infections for PREP 
treatment versus placebo); and (3) the 
incidence of new HIV infections per 
year in populations targeted for PREP 
treatment.
    In order to be cost-effective, the cost 
of PREP per infection avoided should 
be lower than the estimated lifetime 
treatment cost of an HIV-infected 
individual. 
    Evaluation of PREP Drug 
Candidates Based on the 
Formulated Criteria 
    Table 1 shows how the various PREP 
candidates compare based on the 
above criteria. TDF was the ﬁ  rst 
antiviral drug studied in PREP clinical 
trials, based upon pre-clinical data 
showing signiﬁ  cant protection against 
simian immunodeﬁ  ciency virus and 
simian HIV infection when TDF was 
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   Assured  Effectiveness 
   ▪    High genetic barrier : PREP drugs should 
require multiple mutations to cause 
virologic failure (principle of high genetic 
barrier). In this case, the likelihood of 
pre-existing resistant viral strains in the 
inoculum is low. 
  ▪   Unique resistance proﬁ  le : Ideally, there 
is no or limited cross-resistance between 
the resistance proﬁ  le associated with 
the PREP regimen and those associated 
with other antiviral drugs, guaranteeing 
the effectiveness of the PREP regimen in 
settings with some levels of resistance 
at population level. Since all currently 
available antivirals have some cross-
resistance with other drugs, this criteria 
is not being met by any of the current 
antivirals, but the cross-resistance should 
be kept minimal. 
      Limiting the Impact of Selected Drug 
Resistance on Future Treatment 
Response
      In the situation that the individual 
becomes inadvertently infected during 
PREP, there is a risk of selection of drug-
resistant viruses. It is unclear if/how this 
may affect future treatment response, 
but this impact should at any rate be 
minimised and be weighed against the 
beneﬁ  ts of PREP. On a theoretical basis, 
the selected drug-resistant viruses should 
therefore meet the following criteria:
  ▪   Reduced transmissibility : If the 
selected resistant viral strains are less 
transmissible compared to wild-type 
viruses, this may reduce the secondary 
spread of the resistant virus to other 
individuals. Also, this may permit the 
drug to retain antiviral activity as a PREP 
agent even in populations in which many 
potential HIV transmitters are infected 
with viruses resistant to the drug. 
  ▪   Reduced replication capacity : If the 
selected resistant viral strains have a 
reduced replication ﬁ  tness compared 
to wild type, this will result in the 
preferential replication of the drug-
sensitive virus after discontinuation of 
the drug in the infected individual. Over 
time, the drug-resistant virus could be 
reduced to very low levels, comparable 
with those present in the natural 
variation of a wild-type quasi-species. 
These low levels of drug-resistant variants 
may affect treatment response favorably 
when compared with resistance present 
as a major variant. Reduced replication 
capacity is generally related to reduced 
viral load levels, which is associated with 
reduced transmissibility [18,32].
  ▪   Unique resistance proﬁ  le : If the selected 
resistant viral strains have a unique 
resistance pattern not shared by other 
antiretroviral drugs, this will reduce the 
impact on possible future treatment 
response. 
  ▪   High effectiveness of PREP regimen : The 
effectiveness of the PREP regimen at 
preventing a new HIV infection should be 
high. If PREP reduces the number of new 
infections in a population, the number of 
potential resistant strains developed will 
be low. 
  Box 1. PREP Antiviral CriteriaPLoS Medicine  |  www.plosmedicine.org 2001
dosed prior to or after viral exposure 
in small transmission intervention 
studies in simian models [7,8]. The 
oral formulation of TDF meets most 
of the criteria formulated above for 
appropriate PREP candidates. In this 
article we evaluate other antivirals for 
their potential as good PREP drug 
candidates and we make the case that 
lamivudine (3TC) may be a useful 
PREP drug. Given the similarity in 
structure and antiviral proﬁ  le between 
3TC and emtricitabine (FTC), all the 
arguments made for 3TC are also valid 
for FTC, although experience with FTC 
is more limited. 
      Safety proﬁ  le.   Antivirals are known 
to have various side effects. Efavirenz 
often causes central nervous system 
side effects. Nevirapine can have 
life threatening side effects (liver 
toxicity, Stevens-Johnson syndrome). 
The use of protease inhibitors often 
leads to lipodystrophy and other 
metabolic disorders. Nucleoside reverse 
transcriptase inhibitors (NRTIs) come 
with speciﬁ  c side effects depending on 
the drug. 3TC is by far the best tolerated 
and least toxic HIV drug currently 
approved for patient treatment, with 
the best safety record over the longest 
period of time. In addition, 3TC has 
been widely used in prevention of 
mother-to-child transmission studies 
and has also been taken by many 
women who became pregnant while 
on therapy, without apparent injury to 
newborns or the fetus.
      Ease of use.   Most antivirals can be 
administered twice daily, and many can 
be administered once a day. However, 
only three drugs can be administered 
once daily without food restrictions: 
TDF, 3TC, and FTC. 
      Mode of action and pharmacology.   
Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), NRTIs, 
and fusion inhibitors all halt viral 
replication prior to integration of 
viral DNA into host cell DNA. Since 
protease inhibitors halt replication 
after integration takes place, they are 
theoretically less favourable PREP 
candidates. 3TC acts early in the HIV 
replication cycle, before integration, 
and appears to retain antiviral potency 
in both activated and non-activated 
cells. Phosphorylation of 3TC to the 
active triphosphorylated compound 
does not seem to be restricted by either 
the type of host cell or the activation 
stage of the cells [14]. 
      Antiviral proﬁ  le.   A successful PREP 
candidate will need to have a unique 
resistance proﬁ  le. Resistance selected 
by protease inhibitors and NNRTIs 
generally gives rise to broad cross-
resistance to all other drugs in the 
class. In addition, thymidine-associated 
mutations selected by NRTIs confer 
cross-resistance to various other 
NRTIs. 3TC readily selects for the 
M184I/V mutations. These mutations 
confer selective resistance, which 
is largely restricted to 3TC/FTC. 
Although low-level cross-resistance can 
be conferred by the M184V mutation 
in vitro against didanosine (DDI) and 
abacavir, clinical studies suggest that 
the selection of the this mutation does 
not impact the subsequent virologic 
response to DDI [15,16]. For most 
other nucleos(t)ides (zidovudine, 
stavudine, TDF) the antiviral activity 
of the drugs in the presence of 
M184V is slightly enhanced [17]. 
In contrast, the resistance proﬁ  le 
associated with TDF therapy includes 
mutations, such as K65R and T215Y, 
that are associated with broader cross-
resistance across the nucleoside class 
of drugs.
    The candidate should reduce 
HIV transmissibility. Various factors 
are known to be associated with an 
increased transmission of HIV: high 
viraemia [18], concomitant sexually 
transmitted diseases [19], host 
genetic factors [20], and behavioural 
characteristics. However, little is known 
about the factors associated with the 
selective transmission of drug-resistant 
viruses. A recent study comparing 
the prevalence of drug resistance 
mutations among viruses from primary 
HIV-1 infection (PHI) with viruses 
from a representative population 
of potential transmitters found that 
the prevalence of M184V and major 
protease inhibitor mutations was 
signiﬁ  cantly lower in the PHI group. 
For M184V this difference was most 
striking: a prevalence of 10.1% in the 
PHI group versus 70.0% in the treated 
group [21]. This was conﬁ  rmed in a 
European dataset [22]. These data 
suggest a diminished transmission of 
these HIV-1 variants, which may reﬂ  ect 
both their diminished replicative and/
or transmission capacity as well as their 
potential consequence on the viraemia. 
Early reversion to wild-type virus cannot 
  Table 1.   Summary of Some PREP Criteria for Antiviral Compounds Approved for 
Treatment of HIV Infection   
Drug Class Compound Ease of Use Mode of 
Action a
Activity in 
Resting Cells
Cost b (US$ 
per Person-
Year)
 Nucleos(t)ide 
reverse transcriptase 
inhibitors 
Zidovudine BID PRE No 131
Lamivudine QD PRE Yes 53
Stavudine BID PRE No 14
Didanosine QD, empty 
stomach
PRE Yes 142
Abacavir QD PRE Yes 584
Tenofovir disoproxil 
fumarate
QD PRE Yes 301
 Non-nucleoside 
reverse transcriptase 
inhibitors 
Efavirenz QD, empty 
stomach
PRE Yes 316
Nevirapine BID PRE Yes 73
 Protease  inhibitors  Indinavir BID, with food POST No 383
Ritonavir BID, with food POST No 83
Nelﬁ  navir BID, with food POST No 978
Saquinavir BID, with food POST No 989
Lopinavir BID, with food POST No 500
Fosamprenavir QD POST No NA
Tipranavir BID, with food POST No NA
Atazanavir QD, with food POST No NA
 Fusion  inhibitors  Enfuvirtide BID, injections PRE NA NA
  a  PRE: the drug interferes prior to integration of the proviral DNA into the host cell genome; POST: the drug interferes after 
integration of proviral DNA into the host cell genome. 
  b  Lowest cost as reported by [31].
    BID, twice daily dosing; NA, not available; QD, once daily dosing
  doi:10.1371/journal.pmed.0030454.t001 
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be excluded; however, the PHI group 
included patients infected during 
the last six months based on strict 
criteria and long-term persistence of 
transmitted resistance in PHI has been 
shown [23,24]. 
    The candidate must also demonstrate 
proof of principle and effectiveness. In 
the SIMBA study, conducted in Rwanda 
and Uganda, 3TC was administered 
on a daily basis to HIV-negative infants 
from HIV-positive breast-feeding 
mothers (who had received pre-partum 
zidovudine/DDI) for the duration of 
breast-feeding (maximum six months). 
In contrast to earlier results in the 
Petra study, with a similar pre-partum 
maternal intervention, but with no 
infant PREP during breast-feeding, 
virtually no infant infections occurred 
in the SIMBA study [25]. Similar results 
have recently been presented from a 
study conducted in Tanzania [26].
    The candidate should reduce the 
replication capacity of the virus. 
A number of reverse transcriptase 
and protease mutations affect the 
replication capacity of HIV. The NRTI 
resistance mutation M184V and the 
protease inhibitor mutation D30N 
are single mutations associated with 
reduced viral replication compared to 
wild-type virus. These mutant variants 
usually become undetectable within 
weeks of discontinuing therapy and are 
frequently replaced by wild-type virus, 
indicating their in vivo reduced ﬁ  tness 
in the absence of drugs compared to 
the wild-type virus. In the case of the 
protease inhibitor–resistant virus, the 
initial reduction of replication capacity 
can be compensated by the selection of 
additional mutations [27]. The reduced 
replication capacity of the virus granted 
by the M184V mutation persists and 
is often associated with a persistent 
partial antiviral effect during continued 
administration of the drug [28]. The 
diminished replication ﬁ  tness of 
M184V-containing viruses is thought to 
be related to the location of the M184V 
amino acid residue close to the active 
site of the viral reverse transcriptase 
enzyme. The mutation is thought to 
interfere with the replication process 
of the reverse transcriptase enzyme 
through a diminished transcription 
processivity, an increased transcription 
ﬁ  delity resulting in a decreased 
mutation rate, a diminished initiation 
of the reverse transcription reaction, 
and a diminished rate of excision of 
incorporated nucleotides from viral 
DNA [29].
  Cost-Effectiveness
    Hill and co-authors did an analysis to 
determine the conditions under which 
the cost of PREP treatment would be 
lower than the cost of treating people 
for life with highly active antiretroviral 
therapy once HIV infection occurred 
in a sub-Saharan African setting 
without access to PREP [30]. They 
estimated that the lifetime treatment 
cost was US$10,000 over 20 years ($500 
estimated per year, to cover both 
diagnostics and medical expenses).
    The cost per HIV infection prevented 
by PREP was calculated for various HIV 
incidences (between 1%–15%) and for 
different costs of the PREP drug ($50, 
$100, $250, and $500). The results 
are depicted for two efﬁ  cacy rates: see 
Figure 1, where PREP is assumed to cut 
incidence of HIV by 40%, and Figure 2, 
where this efﬁ  cacy rate is set at 80%. 
    The lowest annual drug costs included 
$53 per person-year for generic 3TC, 
$200 for the standard generic treatment 
regimen stavudine/3TC/nevirapine, 
$300 for TDF, and $500 for lopinavir/
ritonavir [31]. With an HIV incidence 
of 1%, and assuming 80% efﬁ  cacy of 
PREP, 125 people would require PREP 
treatment to prevent one HIV infection, 
resulting in a cost per infection avoided, 
in the case of generic 3TC being used, 
of $6,625. In these settings, PREP with 
generic 3TC would be cost-effective 
(costing less than $10,000). 
    In addition, 3TC is also included in 
the World Health Organization list of 
essential drugs for HIV treatment in the 
developing world. Thus, the relevant 
developing country stakeholders for 
PREP clinical trials and PREP approval 
are already familiar with 3TC and have 
experience in its use.
  Combined  PREP  (“Combo-PREP”)
    Recently, promising results were 
shown when combining TDF with FTC 
as PREP, the so-called combo-PREP, 
in an animal model [10]. None of 
six male rhesus macaques who were 
receiving both drugs became infected 
when repeatedly rectally exposed to 
simian HIV, compared to ﬁ  ve of six 
male control macaques who were 
receiving no treatment. These results 
prompted some of the ongoing and 
planned PREP trials to be modiﬁ  ed to 
test Truvada, the combination tablet 
of TFD and FTC, instead of a single 
PREP drug. Results of these trials will 
help elucidate the value of using more 
than one drug in PREP regimens. 
These results should be interpreted 
by also looking at possible downsides 
of combinations of drugs, such as 
increased toxicity and cost. 
    Issues Related to Designing 
PREP Studies
    A randomised trial studying the 
incidence of new HIV infections in a 
group treated with PREP compared 
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  Figure 1.   Cost-Effectiveness of PREP with a 40% Efﬁ  cacy Rate
      This graph shows the cost per infection avoided by PREP (US$) by annual HIV incidence (%) and by 
cost of PREP treatment (US$), assuming PREP cuts incidence of HIV infection by 40%. The striped 
bars indicate that the cost per infection avoided by PREP was over $10,000 and was therefore not 
considered to be cost-effective. PLoS Medicine  |  www.plosmedicine.org 2003
to placebo will address the efﬁ  cacy 
and safety of the drug to prevent HIV 
infection. Although PREP would be 
most beneﬁ  cial and cost-effective in the 
developing world where there is high 
HIV prevalence, a proof of concept 
study is urgently needed and should be 
organized irrespective of the setting. 
Large numbers should be included, 
especially in low HIV incidence 
settings, given that the continued 
counseling on use of other proven 
prevention measures will most certainly 
also reduce HIV incidence.
    Several ethical and logistical issues 
need to be carefully addressed when 
designing a PREP trial, especially in 
resource-poor settings. What about 
the treatment and care of participants 
who become infected during the 
program and of those excluded from 
the trial because they were found to 
be HIV positive at baseline? Proven 
effective prevention interventions 
should be delivered to participants, 
and mechanisms to promote research 
literacy for host communities put in 
place. The studies should be carefully 
discussed and planned in collaboration 
with local communities. In addition, in 
case PREP proves to be efﬁ  cacious and 
would be implemented on a large scale, 
social marketing will be very important 
to promote this prevention measure 
along with others and to educate 
people on proper use of PREP and 
expected outcomes.
    3TC as PREP: Issues for 
Consideration
    Based on the above stated criteria, 
3TC would be an interesting PREP 
drug candidate. However, two areas 
need attention when using 3TC 
as a PREP drug. First, the impact 
on future treatment response of 
individuals infected when exposed 
to 3TC monotherapy should be 
carefully monitored since the currently 
available drug regimens in resource-
poor settings generally include 3TC. 
It remains unclear whether archived 
3TC resistance, overgrown by wild-type 
virus due to its diminished replicative 
capacity, would be again selected 
by 3TC as part of the antiretroviral 
treatment regimen and thus have 
an impact on subsequent treatment 
response. 
    Secondly, the impact of 3TC on the 
course of chronic hepatitis B infection 
should be closely monitored. 3TC was 
the ﬁ  rst nucleoside analogue licensed 
for treatment of chronic hepatitis B 
infection. However, after an initial 
response, resistant hepatitis B virus 
could be selected, resulting in a 
breakthrough infection which may be 
accompanied by acute exacerbation of 
liver disease. Also, acute exacerbation 
of hepatitis with or without hepatic 
decompensation may occur after 
discontinuation of 3TC treatment, as 
is the case with TDF. On the other 
hand, these drugs may be effective in 
prevention of hepatitis B virus infection 
as well as that of HIV. 
  Conclusion
    In this paper, we have formulated 
criteria to which a PREP drug should 
adhere based on theoretical grounds 
and expert opinion. According to these 
criteria, we have argued that 3TC would 
make an interesting PREP drug given 
its relative safety, ease of use, mode 
of action and pharmacology, antiviral 
proﬁ  le, and cost-effectiveness. Whether 
its use will be optimal as monotherapy, 
or in combination with another 
antiviral, is still unknown. Randomised 
clinical trials to evaluate 3TC’s efﬁ  cacy 
in preventing new HIV infections are 
the only way forward.   
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